Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 122.00 | |
5 mg | In stock | $ 313.00 | |
10 mg | In stock | $ 497.00 | |
25 mg | In stock | $ 793.00 | |
50 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 323.00 |
Description | Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1]. |
Targets&IC50 | PDE1B:8.48 μM, PDE9A2:9.99 nM, PDE1C:12.2 μM, PDE9A1:8.19 nM, PDE5A2:81.9 μM, PDE1A3:88.4 μM |
In vitro |
Tovinontrine (IMR-687) (0.03-10 μM) treatment for 6 hours in erythroid K562 cells increases cGMP in a dose-dependent manner.[1] IMR-687 (0.1-10 μM) treatment in erythroid K562 cells for 72 hours induces hemoglobin (HbF) in a dose-dependent manner.[1] |
In vivo | Tovinontrine (IMR-687) (30 mg/kg/day; 30 days) resulted in a more than three-fold increase in the proportion of HbF+ F-cells (8.4% in the vehicle-treated group and 27.3% in the IMR-687 treated group), accompanied by a corresponding two-fold reduction in sickled red blood cells (56.3% in the vehicle-treated group and 24.4% in the IMR-687 treated group).[1] |
Synonyms | IMR-687 |
Molecular Weight | 394.47 |
Formula | C21H26N6O2 |
CAS No. | 2062661-53-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (228.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tovinontrine 2062661-53-2 Metabolism PDE IMR-687 IMR687 IMR 687 inhibitor inhibit